2,000 patients treated with OssDsign® Catalyst in the U.S.

Uppsala, September 13, 2023. OssDsign AB (publ.) today announces that the company’s orthobiologic business continues to accelerate its successful commercialization in the U.S. To this day, 2,000 patients have been treated with the innovative nanosynthetic bone graft OssDsign Catalyst, up from 1,000 patients treated in May.

With 2,000 patients treated, OssDsign Catalyst continues to show exponential growth from earlier records of 1,000 treated patients in May and 500 patients treated in January.

“It is great to see how our orthobiologics business continues its successful commercialization. The accelerating growth of OssDsign Catalyst shows that our differentiated innovation has received a broad market acceptance,” said Morten Henneveld, CEO of OssDsign.

OssDsign Catalyst is a nanosynthetic bone graft that stimulates the formation of healthy bone tissue in spinal fusion surgeries. The graft is composed of a proprietary nanocrystalline structure which is resorbed and replaced by new and healthy bone tissue. The product was launched in the U.S. in August 2021. The market clearance in the U.S. is based on preclinical results that surpass what is typically seen with other synthetic bone grafts in the most demanding preclinical model for spinal fusion – the Boden model. OssDsign continues to accelerate a robust program of gathering clinical evidence anchored by PROPEL, a U.S.-based multi-center prospective spinal fusion registry and TOP FUSION, in which patient enrolment was completed in April 2022.

For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email:

Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser
Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden
Phone: +46 (0)8-463 80 00, email:

About OssDsign
OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give patients back the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button